# v4.18

## Related releases

## Data changes

### Gene

```
GATA2 Background Updated
LMNA Background Updated
LMNA Summary Updated
NHERF1 Background Updated
NHERF1 Summary Updated
POLD1 Background Updated
PRCC Background Updated
PRCC Summary Updated
PRKAR1A Summary Updated
RIOK2 Background Updated
RIOK2 Summary Updated
RNF43 Background Updated
TP53 Background Updated
UBA1 Background Updated
UBA1 Summary Updated
UBTF Background Updated
UBTF Summary Updated
```

### Alteration

```
BRCA1 D749Y Added
BRCA1 E638K Added
BRCA1 V191I, Mutation Effect, Description Updated
BRCA2 N830D Added
CSF3R C-Terminal Truncating Mutations (T738_Q823trunc), Mutation Effect, Description Updated
CSF3R C-Terminal Truncating Mutations (T738_Q823trunc), Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
CSF3R C-Terminal Truncating Mutations (T738_Q823trunc), Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
CSF3R C-Terminal Truncating Mutations (T738_Q823trunc) Added
CSF3R T738_Q823trunc [C-Terminal Truncating Mutations] Name Changed
	 New: T738_Q823trunc [C-Terminal Truncating Mutations]
	 Old: C-Terminal Truncating Mutations (T738_Q823trunc)
GATA2 Truncating Mutations Added
LMNA Amplification Added
MTOR L2427Q, Mutation Effect, Description Updated
MTOR L2427Q, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old: Inconclusive
MTOR L2427Q, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Inconclusive
NHERF1 Truncating Mutations, Mutation Effect, Description Updated
NHERF1 E43G, Mutation Effect, Description Updated
NHERF1 K172N, Mutation Effect, Description Updated
NHERF1 D301V, Mutation Effect, Description Updated
NHERF1 A190D, Mutation Effect, Description Updated
PRCC Amplification, Mutation Effect, Description Updated
PRCC Amplification, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
PRCC Amplification, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRCC Amplification Added
PRKAR1A Deletion Added
PRKAR1A G289E, Mutation Effect, Description Updated
PRKAR1A G289E, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A G289E, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A G289E Added
PRKAR1A A328V, Mutation Effect, Description Updated
PRKAR1A A328V, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A A328V, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A A328V Added
PRKAR1A R335L, Mutation Effect, Description Updated
PRKAR1A R335L, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A R335L, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A R335L Added
PRKAR1A Q285R, Mutation Effect, Description Updated
PRKAR1A Q285R, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A Q285R, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A Q285R Added
PRKAR1A Y175C, Mutation Effect, Description Updated
PRKAR1A Y175C, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A Y175C, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A Y175C Added
PRKAR1A A213T, Mutation Effect, Description Updated
PRKAR1A A213T, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A A213T, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A A213T Added
PRKAR1A G289W, Mutation Effect, Description Updated
PRKAR1A G289W, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A G289W, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A G289W Added
PRKAR1A A213D, Mutation Effect, Description Updated
PRKAR1A A213D, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
PRKAR1A A213D, Mutation Effect, Oncogenic Updated
	 New: Likely Neutral
	 Old:
PRKAR1A A213D Added
RIOK2 Amplification Added
SPOP W131C, Mutation Effect, Description Updated
SPOP W131C, Mutation Effect, Effect Updated
	 New: Likely Loss-of-function
	 Old: Likely Neutral
SPOP W131C, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old: Likely Neutral
UBTF Internal tandem duplication, Mutation Effect, Description Updated
UBTF Internal tandem duplication, Mutation Effect, Effect Updated
	 New: Likely Gain-of-function
	 Old:
UBTF Internal tandem duplication, Mutation Effect, Oncogenic Updated
	 New: Likely
	 Old:
UBTF Internal tandem duplication Added
```

### Evidence

```
BRAF L597, Other Tumor Types, Summary Updated
BRAF L597, All Solid Tumors, Plixorafenib, Description Updated
BRAF K601, Other Tumor Types, Summary Updated
BRAF K601, All Solid Tumors, Plixorafenib, Description Updated
BRAF G469A, G469V, G469R, G464 (non-V600 mutations class II ), All Solid Tumors, Summary Updated
BRAF G469A, G469V, G469R, G464 (non-V600 mutations class II ), All Solid Tumors, Plixorafenib, Description Updated
BRAF V600E, Low-Grade Glioma, NOS, Summary Updated
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, Description Updated
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, FDA Level Updated
	 New: Fda2
	 Old: no
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, Level Updated
	 New: 1
	 Old:
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, Propagation to Other Liquid Tumor Types Updated
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, Propagation to Other Solid Tumor Types Updated
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib 1 Added
BRAF V600E, Low-Grade Glioma, NOS, Dabrafenib + Trametinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib, Description Updated
EGFR L858R, Non-Small Cell Lung Cancer, Summary Updated
EGFR L858R, Other Tumor Types, Summary Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy 2 Added
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, FDA Level Updated
	 New: Fda2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Level Updated
	 New: 2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Solid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib 2 Added
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib, Description Updated
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib, Level Updated
	 New: 2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Liquid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Solid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib 2 Added
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib, Description Updated
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib, Level Updated
	 New: 2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Liquid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Solid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib 2 Added
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib, Description Updated
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib, Level Updated
	 New: 2
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Liquid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Solid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib 3A Added
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Description Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, FDA Level Updated
	 New: Fda3
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Level Updated
	 New: 3A
	 Old:
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Liquid Tumor Types Updated
EGFR G719, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Solid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy 1 Added
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, Level Updated
	 New: 1
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Osimertinib + Chemotherapy, Propagation to Other Solid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy 2 Added
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Level Updated
	 New: 2
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Solid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib 3A Added
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Description Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, FDA Level Updated
	 New: Fda3
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Level Updated
	 New: 3A
	 Old:
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Liquid Tumor Types Updated
EGFR L858R, 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Solid Tumor Types Updated
EGFR 729_761del [Exon 19 in-frame deletions], Non-Small Cell Lung Cancer, Summary Updated
EGFR 729_761del [Exon 19 in-frame deletions], Other Tumor Types, Summary Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy 2 Added
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, FDA Level Updated
	 New: Fda2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Level Updated
	 New: 2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Solid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib 2 Added
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib, Description Updated
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib, Level Updated
	 New: 2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Liquid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Solid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib 2 Added
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib, Description Updated
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib, Level Updated
	 New: 2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Liquid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Solid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib 2 Added
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib, Description Updated
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib, Level Updated
	 New: 2
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Liquid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Solid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib 3A Added
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Description Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, FDA Level Updated
	 New: Fda3
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Level Updated
	 New: 3A
	 Old:
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Liquid Tumor Types Updated
EGFR S768I, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Solid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib 2 Added
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib, Description Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib, Level Updated
	 New: 2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Liquid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Dacomitinib, Propagation to Other Solid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib 2 Added
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib, Description Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib, Level Updated
	 New: 2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Liquid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Erlotinib, Propagation to Other Solid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib 2 Added
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib, Description Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib, Level Updated
	 New: 2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Liquid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Gefitinib, Propagation to Other Solid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy 2 Added
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Description Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, FDA Level Updated
	 New: Fda2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Level Updated
	 New: 2
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Liquid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Chemotherapy, Propagation to Other Solid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib 3A Added
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Description Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, FDA Level Updated
	 New: Fda3
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Level Updated
	 New: 3A
	 Old:
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Liquid Tumor Types Updated
EGFR L861Q, Non-Small Cell Lung Cancer, Amivantamab + Lazertinib, Propagation to Other Solid Tumor Types Updated
ERBB2 Amplification, Biliary Tract Cancer, NOS, Summary Updated
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab 2 Added
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab, Description Updated
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab, FDA Level Updated
	 New: Fda2
	 Old:
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab, Level Updated
	 New: 2
	 Old:
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab, Propagation to Other Liquid Tumor Types Updated
ERBB2 Amplification, Biliary Tract Cancer, NOS, Tucatinib + Trastuzumab, Propagation to Other Solid Tumor Types Updated
GATA2 Gene Type, Tumor Suppressor Updated
KRAS G12C, Hepatobiliary Cancer, Summary Updated
KRAS G12C, Hepatobiliary Cancer, Adagrasib 2 Added
KRAS G12C, Hepatobiliary Cancer, Adagrasib, Description Updated
KRAS G12C, Hepatobiliary Cancer, Adagrasib, FDA Level Updated
	 New: Fda2
	 Old:
KRAS G12C, Hepatobiliary Cancer, Adagrasib, Level Updated
	 New: 2
	 Old:
KRAS G12C, Hepatobiliary Cancer, Adagrasib, Propagation to Other Liquid Tumor Types Updated
KRAS G12C, Hepatobiliary Cancer, Adagrasib, Propagation to Other Solid Tumor Types Updated
KRAS G12C, Colorectal Cancer, Adagrasib + Panitumumab, Sotorasib + Cetuximab, Sotorasib + Panitumumab Name Changed
	 New: 0a7b3eb1-d1f0-4511-aaac-9a696955bf57 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3, 7d507726-ed2e-4f65-a35a-0e1e88984278 + 5fce3074-e420-4c36-9603-2423daf20118, 7d507726-ed2e-4f65-a35a-0e1e88984278 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3
	 Old: 0a7b3eb1-d1f0-4511-aaac-9a696955bf57 + 5fce3074-e420-4c36-9603-2423daf20118, 0a7b3eb1-d1f0-4511-aaac-9a696955bf57 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3, 7d507726-ed2e-4f65-a35a-0e1e88984278 + 5fce3074-e420-4c36-9603-2423daf20118, 7d507726-ed2e-4f65-a35a-0e1e88984278 + d7b1d12a-e942-4801-bb64-916c9bdfaaf3
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab 1 Added
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab, Description Updated
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab, FDA Level Updated
	 New: Fda2
	 Old:
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab, Level Updated
	 New: 1
	 Old:
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab, Propagation to Other Liquid Tumor Types Updated
KRAS G12C, Colorectal Cancer, Adagrasib + Cetuximab, Propagation to Other Solid Tumor Types Updated
KRAS G12C, Colorectal Cancer, Summary Updated
KRAS G12C, Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus, Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon Name Changed
	 New: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon
	 Old: Esophagogastric Cancer, Anal Cancer, Gastrointestinal Neuroendocrine Tumors of the Esophagus/Stomach, Small Bowel Cancer, Tubular Adenoma of the Colon, Hepatobiliary Cancer
LMNA Gene Type, Oncogene Updated
NTRK1 Fusions, All Solid Tumors, Summary Updated
NTRK1 Fusions, All Solid Tumors, Repotrectinib, Description Updated
NTRK1 Fusions, All Solid Tumors, Repotrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK1 Fusions, All Solid Tumors, Repotrectinib, Level Updated
	 New: 1
	 Old: 3A
NTRK1 Fusions, All Solid Tumors, Repotrectinib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
NTRK1 Oncogenic Mutations, All Tumors, Summary Updated
NTRK2 Oncogenic Mutations, All Tumors, Summary Updated
NTRK2 Fusions, All Solid Tumors, Summary Updated
NTRK2 Fusions, All Solid Tumors, Repotrectinib, Description Updated
NTRK2 Fusions, All Solid Tumors, Repotrectinib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
NTRK2 Fusions, All Solid Tumors, Repotrectinib, Level Updated
	 New: 1
	 Old: 3A
NTRK2 Fusions, All Solid Tumors, Repotrectinib, Propagation to Other Liquid Tumor Types Updated
NTRK3 Oncogenic Mutations, All Tumors, Summary Updated
NTRK3 Fusions, Other Tumor Types, Summary Updated
NTRK3 Fusions, All Solid Tumors, Summary Updated
NTRK3 Fusions, All Solid Tumors, Repotrectinib, Description Updated
NTRK3 Fusions, All Solid Tumors, Repotrectinib, FDA Level Updated
	 New: Fda2
	 Old: Fda3
NTRK3 Fusions, All Solid Tumors, Repotrectinib, Level Updated
	 New: 1
	 Old: 3A
NTRK3 Fusions, All Solid Tumors, Repotrectinib, Propagation to Other Liquid Tumor Types Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, Level Updated
	 New: 1
	 Old:
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab 1 Added
Other Biomarkers MSI-H [Microsatellite Instability-High], Colorectal Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, Description Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old: no
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, Level Updated
	 New: 1
	 Old:
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, Propagation to Other Liquid Tumor Types Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, Propagation to Other Solid Tumor Types Updated
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab 1 Added
Other Biomarkers MSI-H [Microsatellite Instability-High], Endometrial Cancer, Pembrolizumab, FDA Level Updated
	 New: Fda2
	 Old:
PRCC Gene Type, Oncogene Updated
PRKAR1A Gene Type, Tumor Suppressor Updated
RET Oncogenic Mutations, Medullary Thyroid Cancer, Selpercatinib, Description Updated
RET Fusions, Thyroid Cancer, Selpercatinib, Description Updated
RET Fusions, All Solid Tumors Name Changed
	 New: All Solid Tumors
	 Old: All Solid Tumors {excluding Non-Small Cell Lung Cancer, Thyroid Cancer}
RIOK2 Gene Type, Oncogene Updated
UBA1 Gene Type, Oncogene Updated
UBTF Gene Type, Oncogene Updated
```
